News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
An upgraded, state-of-the-art integrated app, helps easy discovery of expert surgeons for convenient in-clinic or online consultation
BioFluidica LiquidScan harnesses the power of microfluidics
Ind-Ra maintains a neutral outlook for healthcare in FY23
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Drones will be used in the Gurugram and Mumbai region to transport pathology samples
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
It is an application to automate statistical analysis and reporting for clinical research.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
